CLRB - Cellectar's CLR 131 an Orphan Drug in European for rare blood cancer

The EMA has adopted a positive opinion for Cellectar Biosciences' (CLRB) CLR 131 orphan designation for the treatment of Waldenstrom’s Macroglobulinemia ((WM)). Cellectar has initiated a pivotal trial evaluating CLR 131 in WM patients that have failed or had a suboptimal response to a Bruton’s tyrosine kinase inhibitor.WM is a lymphoma, or cancer of the lymphatic system. It is a rare and incurable disease defined by specific genotypic subtype. The disease occurs in a type of white blood cell called a B-lymphocyte or B-cell, which normally matures into a plasma cell whose job is to manufacture immunoglobulins (antibodies) to help the body fight infection. The FDA granted CLR 131 Fast Track Designation and Orphan Drug Designation for relapsed/refractory WM, multiple myeloma and diffuse large B-cell lymphoma.Shares up 2% premarket.

For further details see:

Cellectar's CLR 131 an Orphan Drug in European for rare blood cancer